Literature DB >> 21732217

Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.

Wai Kwan Siu1, Chun Yiu Law, Ching Wan Lam, Chloe Miu Mak, Gary Wing Kin Wong, Andrew Yiu Yan Ho, Kwok Yip Ho, Ka Tai Loo, Sin Chuen Chiu, Louis Tsun Cheung Chow, Sui Fan Tong, Albert Yan Wo Chan.   

Abstract

Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is an autosomal dominant disease characterized by the occurrences of parathyroid tumors and ossifying fibroma of maxilla/mandible. It is caused by mutations in CDC73 gene and mutation carriers are at increased risk of parathyroid carcinoma. Hyperparathyroidism could be the sole manifestation. We reported two Chinese patients having parathyroid neoplasm with equivocal malignant potential and parathyroid carcinoma respectively with both germline and somatic CDC73 mutations detected. Both of them presented with severe hypercalcemia and primary hyperparathyroidism with no other HPT-JT associated tumors and negative family history. We identified one novel germline mutation CDC73 NM_024529.4: c.1475G > A; NP_078805.3: p.Trp492X and one novel somatic mutation CDC73 NM_024529.4: c.142G > T; NP_078805.3: p.Glu48X. The other germline mutation CDC73 NM_024529.4: c.226C > T; NP_078805.3: p.Arg76X and somatic mutation CDC73 NM_024529.4: c.85delG; NP_078805.3: p.Glu29SerfsX8 were previously reported. This is the first report of CDC73 mutations in the Chinese population. Genetic analysis is reliable to confirm the underlying hereditary basis of hyperparathyroidism. By identification of mutations, the patient and the family members could benefit from regular surveillance for early detection of tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732217     DOI: 10.1007/s10689-011-9466-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

1.  The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred.

Authors:  B M Cavaco; L Barros; A A Pannett; L Ruas; M Carvalheiro; M M Ruas; T Krausz; M A Santos; L G Sobrinho; V Leite; R V Thakker
Journal:  QJM       Date:  2001-04

Review 2.  Hyperparathyroid and hypoparathyroid disorders.

Authors:  S J Marx
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

3.  The surgical strategy and the molecular analysis of patients with parathyroid cancer.

Authors:  Keisuke Enomoto; Shinya Uchino; Akiko Ito; Shin Watanabe; Hiroshi Shibuya; Yukie Enomoto; Shiro Noguchi
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

4.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Authors:  J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs
Journal:  Nat Genet       Date:  2002-11-18       Impact factor: 38.330

5.  Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome.

Authors:  C E Jackson; R A Norum; S B Boyd; G B Talpos; S D Wilson; R T Taggart; L E Mallette
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

6.  Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.

Authors:  Janneke E Witteveen; Neveen A T Hamdy; Olaf M Dekkers; Job Kievit; Tom van Wezel; Bin T Teh; Johannes A Romijn; Hans Morreau
Journal:  Mod Pathol       Date:  2011-01-14       Impact factor: 7.842

7.  Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families.

Authors:  B T Teh; F Farnebo; S Twigg; A Höög; S Kytölä; E Korpi-Hyövälti; F K Wong; J Nordenström; L Grimelius; K Sandelin; B Robinson; L O Farnebo; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

8.  Hyperparathyroidism-jaw tumor syndrome: a case report.

Authors:  N Rekik; B Ben Naceur; M Mnif; F Mnif; H Mnif; T Boudawara; M Abid
Journal:  Ann Endocrinol (Paris)       Date:  2009-11-25       Impact factor: 2.478

Review 9.  Parafibromin--functional insights.

Authors:  P J Newey; M R Bowl; R V Thakker
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

10.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

View more
  9 in total

Review 1.  Systematic review of oral manifestations related to hyperparathyroidism.

Authors:  Benjamin Palla; Egon Burian; Riham Fliefel; Sven Otto
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

Review 2.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

Review 3.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

Review 4.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

5.  A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.

Authors:  Alisha Kapur; Narendra Singh; Ozgur Mete; Robert A Hegele; I George Fantus
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

6.  Parafibromin Abnormalities in Ossifying Fibroma.

Authors:  Jessica Costa-Guda; Chetanya Pandya; Maya Strahl; Patricia Taik; Robert Sebra; Rong Chen; Andrew V Uzilov; Andrew Arnold
Journal:  J Endocr Soc       Date:  2021-05-08

7.  Identification and functional characterization of three NoLS (nucleolar localisation signals) mutations of the CDC73 gene.

Authors:  Valerio Pazienza; Annamaria la Torre; Filomena Baorda; Michela Alfarano; Massimiliano Chetta; Lucia Anna Muscarella; Claudia Battista; Massimiliano Copetti; Dieter Kotzot; Klaus Kapelari; Dalia Al-Abdulrazzaq; Kusiel Perlman; Etienne Sochett; David E C Cole; Fabio Pellegrini; Lucie Canaff; Geoffrey N Hendy; Leonardo D'Agruma; Leopoldo Zelante; Massimo Carella; Alfredo Scillitani; Vito Guarnieri
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

8.  Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases.

Authors:  Peisong Wang; Shuai Xue; Shuo Wang; Zhi Lv; Xianying Meng; Guimin Wang; Wei Meng; Jia Liu; Guang Chen
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

Review 9.  Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

Authors:  Luís Cardoso; Mark Stevenson; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2017-09-25       Impact factor: 4.878

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.